AAAAAA
Results:
1-14
|
Results: 14
Authors:
Flaherty, KT
Stevenson, JP
O'Dwyer, PJ
Citation: Kt. Flaherty et al., Antisense therapeutics: lessons from early clinical trials, CURR OPIN O, 13(6), 2001, pp. 499-505
Authors:
Robnett, TJ
Machtay, M
Stevenson, JP
Algazy, KM
Hahn, SM
Citation: Tj. Robnett et al., Factors affecting the risk of brain metastases after definitive chemoradiation for locally advanced non-small-cell lung carcinoma, J CL ONCOL, 19(5), 2001, pp. 1344-1349
Authors:
Stevenson, JP
Redlinger, M
Kluijtmans, LAJ
Sun, WJ
Algazy, K
Giantonio, B
Haller, DG
Hardy, C
Whitehead, AS
O'Dwyer, PJ
Citation: Jp. Stevenson et al., Phase I clinical and pharmacogenetic trial of irinotecan and raltitrexed administered every 21 days to patients with cancer, J CL ONCOL, 19(20), 2001, pp. 4081-4087
Authors:
Stevenson, JP
Rutnakornpituk, M
Vadala, M
Esker, AR
Charles, SW
Wells, S
Dailey, JP
Riffle, JS
Citation: Jp. Stevenson et al., Magnetic cobalt dispersions in poly(dimethylsiloxane) fluids, J MAGN MAGN, 225(1-2), 2001, pp. 47-58
Authors:
O'Dwyer, PJ
Stevenson, JP
Haller, DG
Rotman, N
Giantonio, BJ
Citation: Pj. O'Dwyer et al., Follow-up of stage B and C colorectal cancer in the United States and France, SEMIN ONCOL, 28(1), 2001, pp. 45-49
Authors:
Sun, WJ
Stevenson, JP
Gallagher, M
Giantonio, B
Algazy, K
Haller, D
Vaughn, D
Raskay, BJ
O'Dwyer, PJ
Citation: Wj. Sun et al., A phase I trial of topotecan and gemcitabine administered weekly for 3 consecutive weeks to patients with advanced tumors, CANCER, 92(2), 2001, pp. 414-419
Authors:
Stevenson, JP
Redlinger, M
Sun, WJ
Haller, D
O'Dwyer, PJ
Citation: Jp. Stevenson et al., Irinotecan and UFT/leucovorin in patients with advanced cancers, ONCOLOGY-NY, 14(10), 2000, pp. 91-92
Authors:
O'Dwyer, PJ
Stevenson, JP
Johnson, SW
Citation: Pj. O'Dwyer et al., Clinical pharmacokinetics and administration of established platinum drugs, DRUGS, 59, 2000, pp. 19-27
Authors:
O'Dwyer, PJ
Stevenson, JP
Johnson, SW
Citation: Pj. O'Dwyer et al., Clinical experience - DACH-based platinum drugs, CANC DRUG, 7, 2000, pp. 231-249
Authors:
O'Dwyer, PJ
Stevenson, JP
Gallagher, M
Cassella, A
Vasilevskaya, I
Monia, BP
Holmlund, J
Dorr, FA
Yao, KS
Citation: Pj. O'Dwyer et al., c-raf-1 depletion and tumor responses in patients treated with the c-raf-1antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A), CLIN CANC R, 5(12), 1999, pp. 3977-3982
Authors:
Stevenson, JP
DeMaria, D
Sludden, J
Kaye, SB
Paz-Ares, L
Grochow, LB
McDonald, A
Selinger, K
Wissel, P
O'Dwyer, PJ
Twelves, C
Citation: Jp. Stevenson et al., Phase I pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion, ANN ONCOL, 10(3), 1999, pp. 339-344
Authors:
Stevenson, JP
Yao, KS
Gallagher, M
Friedland, D
Mitchell, EP
Cassella, A
Monia, B
Kwoh, TJ
Yu, R
Holmlund, J
Dorr, FA
O'Dwyer, PJ
Citation: Jp. Stevenson et al., Phase I clinical pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A), J CL ONCOL, 17(7), 1999, pp. 2227-2236
Authors:
Stevenson, JP
DeMaria, D
Reilly, D
Purvis, JD
Graham, MA
Lockwood, G
Drozd, M
O'Dwyer, PJ
Citation: Jp. Stevenson et al., Phase I/pharmacokinetic trial of the novel thioxanthone SR233377 (WIN33377) on a 5-day schedule, CANC CHEMOT, 44(3), 1999, pp. 228-234
Authors:
O'Dwyer, PJ
Stevenson, JP
Citation: Pj. O'Dwyer et Jp. Stevenson, Chemotherapy of advanced colorectal cancer, CANC TREAT, 98, 1998, pp. 111-152
Risultati:
1-14
|